Miller Robert J H, Howlett Jonathan G
Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
Curr Opin Cardiol. 2017 Mar;32(2):209-216. doi: 10.1097/HCO.0000000000000368.
Measurement of heart rate (HR) and rhythm is used to identify patients at increased risk of disease progression, guide selection of treatments and gauge response to therapy.
Lowering HR with a pure HR lowering agent (ivabradine) in heart failure with reduced ejection fraction (HFrEF) and sinus rate more than 70 beats/min despite beta blockade has been shown to improve outcomes. Additionally, coadministration of ivabradine and beta blockade may enhance symptoms and HR control. In the case of patients with heart failure and preserved ejection fraction (HFpEF), or with paced rhythm, optimal HR control is not known. Also, in atrial fibrillation the relationship between HR and outcomes is not clear and minimal evidence for HR reduction to less than 100 beats/min exists. Reasons for this disconnect between atrial fibrillation and sinus rhythm are not known.
HR continues to be a critical vital sign in assessment and forms the basis for a treatment target in patients with HFrEF at rates more than 70 beats/min. The target for HR patients with HFpEF and those who are paced continuously or in atrial fibrillation is less clear and at present is recommended to be in the 60-100 beats/min range at rest. Further study is needed to refine treatment strategies in these latter patients.
测量心率(HR)和心律用于识别疾病进展风险增加的患者、指导治疗选择并评估治疗反应。
在射血分数降低的心力衰竭(HFrEF)且尽管使用了β受体阻滞剂但窦性心率超过70次/分钟的患者中,使用单纯降低心率的药物(伊伐布雷定)降低心率已被证明可改善预后。此外,伊伐布雷定与β受体阻滞剂联合使用可能会增强症状控制和心率控制。对于射血分数保留的心力衰竭(HFpEF)患者或有起搏心律的患者,最佳心率控制尚不清楚。同样,在心房颤动中,心率与预后之间的关系尚不清楚,将心率降至低于100次/分钟的证据很少。心房颤动与窦性心律之间这种脱节的原因尚不清楚。
心率仍然是评估中的一项关键生命体征,并且是心率超过70次/分钟的HFrEF患者治疗目标的基础。HFpEF患者以及持续起搏或心房颤动患者的心率目标尚不清楚,目前建议静息心率在60-100次/分钟范围内。需要进一步研究以完善后一类患者的治疗策略。